The Cleveland Clinic Foundation's (CCF) Lone Atrial Fibrillation (AFIB) GWAS Study

Blood samples were taken from patients who have lone atrial fibrillation. DNA samples were processed with Illumina Hap550 and Hap 610 chips.]]>
Patients who came to Cleveland Clinic for cardiac treatment were voluntarily enrolled in a lone Atrial Fibrillation (AF) bio-repository, including those with AF without significant Structural Heart Disease (SHD) were included in this study. Patients included in this study were at least 18 years of age, had a history of AF without SHD, no significant coronary artery disease (<50% coronary artery stenosis if cardiac catheterization was performed, or a normal stress test); and normal left ventricular function (LVEF ≥50%). Patients were excluded if they had structural heart disease or congenital heart disease (except for an isolated patent foramen ovale with normal right heart chambers); significant valvular disease (>2+ regurgitation or any valve stenosis); coronary artery stenosis >50%, or prior percutaneous coronary intervention or coronary artery bypass grafting. Patients with hypertension were not excluded. The study was approved by the Cleveland Clinic Institutional Review Board and performed in accordance with institutional guidelines. All patients signed written informed consent for study of their genetic and clinical data.]]>